Immediate Evolocumab Improves LDL Targets but Not Outcomes in Acute MI
In the AMUNDSEN trial, patients with acute myocardial infarction who received an immediate injection of evolocumab before percutaneous coronary intervention were more likely to achieve LDL cholesterol targets at 1 year than those on standard care. However, the rate of all-cause death or unplanned cardiovascular hospitalization was similar between groups. The findings indicate that rapid lipid lowering does not translate into short-term clinical benefit.
The AMUNDSEN trial enrolled more than 2,100 high-risk heart attack patients, administering evolocumab immediately before catheterization. While the treatment group showed dramatically better LDL cholesterol control at one year, the primary clinical endpoint — death or unplanned cardiovascular hospitalization — showed no meaningful difference between arms. Notably, only 3.8% of control patients later received a PCSK9 inhibitor during follow-up, suggesting hospitalization may be a critical window for accessing these therapies. The findings were presented at the ESC Congress in Munich and published simultaneously in JAMA, challenging the "strike early and strike strong" approach to lipid management in acute coronary syndromes.
This trial may influence how cardiologists sequence lipid-lowering therapy after heart attacks, potentially tempering enthusiasm for immediate PCSK9 inhibitor administration in the cath lab. Patients could benefit from more measured treatment approaches that avoid unnecessary costs, while healthcare systems may reconsider resource allocation. However, the low crossover rate in the control group raises questions about real-world access to these medications, which could affect long-term outcomes for patients who miss the hospitalization window for initiating therapy.